Oxford Biomedica (OXB) Competitors

Faron Pharmaceuticals Oy (LON:FARN) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.

Does the MarketBeat Community favor FARN or OXB?

Oxford Biomedica received 41 more outperform votes than Faron Pharmaceuticals Oy when rated by MarketBeat users. However, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 67.04% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Faron Pharmaceuticals Oy	Outperform Votes 317 77.51%	Underperform Votes 92 22.49%
Oxford Biomedica	Outperform Votes 358 67.04%	Underperform Votes 176 32.96%

Which has stronger earnings and valuation, FARN or OXB?

Faron Pharmaceuticals Oy has higher earnings, but lower revenue than Oxford Biomedica. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	-£725K	-301.55	-£29.34M	-£0.42	-785.71
Oxford Biomedica	£119.02M	2.21	-£61.63M	-£0.46	-592.39

Do insiders and institutionals hold more shares of FARN or OXB?

13.1% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 67.1% of Oxford Biomedica shares are held by institutional investors. 44.0% of Faron Pharmaceuticals Oy shares are held by company insiders. Comparatively, 8.7% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, FARN or OXB?

Faron Pharmaceuticals Oy has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Do analysts rate FARN or OXB?

Oxford Biomedica has a consensus price target of GBX 752.50, suggesting a potential upside of 176.15%. Given Faron Pharmaceuticals Oy's higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is FARN or OXB more profitable?

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Faron Pharmaceuticals Oy's net margin of -51.78%. Oxford Biomedica's return on equity of 0.00% beat Faron Pharmaceuticals Oy's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	N/A	-113.62%
Oxford Biomedica	-51.78%	-30.64%	-12.05%

Does the media favor FARN or OXB?

In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 7 mentions for Faron Pharmaceuticals Oy and 5 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.58 beat Faron Pharmaceuticals Oy's score of 0.22 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Faron Pharmaceuticals Oy	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oxford Biomedica beats Faron Pharmaceuticals Oy on 9 of the 17 factors compared between the two stocks.